|
Press Releases |
|
|
|
Monday, June 20, 2016 |
|
AbbVie, Eisai, and EA Pharma Obtain Additional Approval for New Dosing Regimen of Fully Human Anti-TNF Monoclonal Antibody Humira in Patients with Crohn's Disease |
AbbVie GK, Eisai Co., Ltd., and its subsidiary EA Pharma Co., Ltd. today announced the additional approval for a new dosing regimen of Humira Pre-filled Syringe 40 mg/0.8 mL for Subcutaneous Injection, a fully human anti-TNF monoclonal antibody formulation, in patients with moderate or severe Crohn's disease who become less responsive to treatment with 40 mg every two weeks to double the dose to 80 mg every two weeks. more info >> |
|
Thursday, June 16, 2016 |
|
Eisai Launches New Oral Suspension Formulation for Antiepileptic Drug Fycompa (Perampanel) in the United States |
Eisai Co., Ltd. announced today that it has launched Fycompa (perampanel) Oral Suspension, a new formulation of its in-house-discovered antiepileptic drug (AED) Fycompa, in the United States. more info >> |
|
エーザイ、米国において抗てんかん剤「Fycompa」経口懸濁液を発売 |
エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫)は、本日、米国において、自社創製の新規抗てんかん剤「Fycompa(R) Oral Suspension(経口懸濁液)」(一般名:ペランパネル、日本製品名「フィコンパ(R)」)を新発売しましたのでお知らせします。 more info >> |
|
Wednesday, June 15, 2016 |
|
エーザイ、人事異動ならびに組織改編(2016年6月17日付、2016年7月1日付)を発表 |
エーザイ株式会社 人事異動ならびに組織改編(2016年6月17日付、2016年7月1日付)を発表しました。 more info >> |
|
Friday, June 3, 2016 |
|
Eisai Inc. Enters Into Collaboration Agreement to Co-Promote Eisai's Anticancer Agent Lenvima in Combination with Evorolimus as Treatment for Advanced Renal Cell Carcinoma in the United States |
Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has entered into an agreement with Novartis Pharmaceuticals Corporation, a U.S. affiliate of Novartis AG, to collaborate on commercial and medical affairs activities for Eisai's in-house developed novel anticancer agent Lenvima and the anticancer agent everolimus in the United States. more info >> |
|
Wednesday, June 1, 2016 |
|
エーザイ、抗がん剤「ハラヴェン(R)」 フィリピンにおいて新たに「悪性軟部腫瘍」に関する効能・効果の承認を取得 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、このたび、フィリピンの販売子会社である HI-Eisai Pharmaceutical, Inc.が、自社創製の抗がん剤 「ハラヴェン(R)」 (一般名:エリブリンメシル酸塩)について、フィリピンにおいて、新たに「悪性軟部腫瘍」の効能・効果の承認を取得したことをお知らせします。 more info >> |
|
アッヴィとエーザイ子会社の EA ファーマ、ヒト型抗ヒト TNFα モノクローナル抗体「ヒュミラ(R)」の消化器疾患領域における共同プロモーションを開始 |
アッヴィ合同会社とエーザイ株式会社およびエーザイ子会社であるEA ファーマ株式会社は、本日より、ヒト型抗ヒト TNFαモノクローナル抗体「ヒュミラ(R)」の消化器疾患領域の適応症について、EA ファーマとアッヴィが共同プロモーションを開始することをお知らせします。 more info >> |
|
AbbVie and Eisai Subsidiary EA Pharma Commence Co-promotion of Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA in the Field of Gastrointestinal Disease |
AbbVie GK, Eisai Co., Ltd. and its subsidiary EA Pharma Co., Ltd., announced that EA Pharma and AbbVie will commence the co-promotion of fully human anti-TNF-alpha monoclonal antibody HUMIRA for indications in the field of gastrointestinal disease (ulcerative colitis, Crohn's disease, intestinal Behcet's disease) as of today. more info >> |
|
Wednesday, May 25, 2016 |
|
Eisai to Launch In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) |
Eisai Co., Ltd. announced today that it will launch its in-house-discovered antiepileptic drug (AED) Fycompa Tablets 2 mg and 4 mg (perampanel hydrate) as an adjunctive therapy for partial-onset seizures (including secondarily generalized seizures) or primary generalized tonic-clonic seizures in patients with epilepsy showing inadequate response to other AEDs in Japan on May 26, 2016. more info >> |
|
エーザイ、自社創製の新規抗てんかん剤「フィコンパ」を発売 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、日本において、「他の抗てんかん薬で十分な効果が認められないてんかん患者の部分発作および強直間代発作に対する抗てんかん薬との併用療法」を効能・効果とする、自社創製の新規抗てんかん剤「フィコンパ(R)錠 2mg」「フィコンパ(R)錠 4mg」」)を5月26日に新発売します。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
CITIC Telecom CPC Garners Multiple Ecosystem Partners Awards Reinforces Collaborative Capabilities, Drives Breakthrough Innovation & Shares Sustainable Development Results
Apr 29, 2024 22:00 HKT/SGT
|
|
|
FTLife Pre-Announces Name Change to Chow Tai Fook Life Insurance Company Limited
Apr 29, 2024 21:47: JST
|
|
|
富通保险宣布将更名为周大福人寿保险有限公司
Apr 29, 2024 21:04 HKT/SGT
|
|
|
富通保險宣佈將更名為周大福人壽保險有限公司
Apr 29, 2024 20:57 HKT/SGT
|
|
|
FTLife Pre-Announces Name Change to Chow Tai Fook Life Insurance Company Limited
Apr 29, 2024 20:47 HKT/SGT
|
|
|
INNIO Group's 2023 Sustainability Report: Progress in Implementing Corporate Sustainability Goals
Apr 29, 2024 20:39 HKT/SGT
|
|
|
Q&M Dental Enhances its Digital Capabilities by Integrating Align Technology's Newest iTero Lumina(TM) Intraoral Scanner Across Dental Clinics in Singapore
Apr 29, 2024 20:00: JST
|
|
|
Hong Kong International Licensing Show creates cross-industry business opportunities
Apr 29, 2024 19:00 HKT/SGT
|
|
|
Q&M Dental Enhances its Digital Capabilities by Integrating Align Technology's Newest iTero Lumina(TM) Intraoral Scanner Across Dental Clinics in Singapore
Apr 29, 2024 19:00 HKT/SGT
|
|
|
「香港智营设计大赏2024」公布得奖名单
Apr 29, 2024 19:00 HKT/SGT
|
|
|
「香港智營設計大賞2024」公佈得獎名單
Apr 29, 2024 19:00 HKT/SGT
|
|
|
Rockbird media Presents HR Leaders & HR Tech Strategy Meeting 2024: 'Rehumanizing Work with Emerging Technologies' in Manila
Apr 29, 2024 18:28: JST
|
|
|
Tex Cycle Partners with Evolusi Bersatu to Launch Sabah's First Integrated Scheduled Waste Management Facility
Apr 29, 2024 18:00: JST
|
|
|
SPARX Group Establishes Space Frontiers Second Fund
Apr 29, 2024 18:49 JST
|
|
|
Rockbird media Presents HR Leaders & HR Tech Strategy Meeting 2024: 'Rehumanizing Work with Emerging Technologies' in Manila
Apr 29, 2024 17:28 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|